doi:10.48130/panfungi-0026-0004

[1]

Latgé JP, Chamilos G. 2019. Aspergillus fumigatus and aspergillosis in 2019. Clinical Microbiology Reviews 33(1):e00140-18

doi: 10.1128/cmr.00140-18

[2]

Denning DW. 2024. Global incidence and mortality of severe fungal disease. The Lancet Infectious Diseases 24(7):e428−e438

doi: 10.1016/S1473-3099(23)00692-8

[3]

Dagenais TRT, Keller NP. 2009. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clinical Microbiology Reviews 22(3):447−465

doi: 10.1128/CMR.00055-08

[4]

Schwarz MCR, Moskaluk AE, Daniels JB, VandeWoude S, Reynolds MM. 2024. Current analytical methods and challenges for the clinical diagnosis of invasive pulmonary aspergillosis infection. Journal of Fungi 10(12):829

doi: 10.3390/jof10120829

[5]

Sati H, Beardsley J, Alastruey-Izquierdo A, Alffenaar JW, Morrissey O, et al. 2022. WHO fungal priority pathogens list to guide research development and public health. World Health Organization (WHO), Geneva. doi: 10.13140/RG.2.2.31126.63040

[6]

Fan Y, Wang Y, Korfanty GA, Archer M, Xu J. 2021. Genome-wide association analysis for triazole resistance in Aspergillus fumigatus. Pathogens 10(6):701

doi: 10.3390/pathogens10060701

[7]

Kanj A, Abdallah N, Soubani AO. 2018. The spectrum of pulmonary aspergillosis. Respiratory Medicine 141:121−131

doi: 10.1016/j.rmed.2018.06.029

[8]

Fueyo Álvarez S, Calonge EV, Caballero Velasquez JA, Revelo Rueda AM, Solla Suarez PE, et al. 2025. Current challenges in the treatment of invasive aspergillosis in geriatric patients. Journal of Fungi 11(7):480

doi: 10.3390/jof11070480

[9]

Deigendesch N, Costa Nunez J, Stenzel W. 2018. Parasitic and fungal infections. In Handbook of Clinical Neurology. Vol. 145. Amsterdam: Elsevier. pp. 245–262 doi: 10.1016/B978-0-12-802395-2.00018-3

[10]

Jenks JD, Nam HH, Hoenigl M. 2021. Invasive aspergillosis in critically ill patients: review of definitions and diagnostic approaches. Mycoses 64(9):1002−1014

doi: 10.1111/myc.13274

[11]

Kazeminejad Z, Marzi M, Shiroudi A, Kouhpayeh SA, Farjam M, et al. 2022. Novel 1, 2, 4-triazoles as antifungal agents. BioMed Research International 2022:4584846

doi: 10.1155/2022/4584846

[12]

Emami S, Tavangar P, Keighobadi M. 2017. An overview of azoles targeting sterol 14α-demethylase for antileishmanial therapy. European Journal of Medicinal Chemistry 135:241−259

doi: 10.1016/j.ejmech.2017.04.044

[13]

Siswina T, Miranti Rustama M, Sumiarsa D, Kurnia D. 2023. Phytochemical profiling of Piper crocatum and its antifungal mechanism action as Lanosterol 14 alpha demethylase CYP51 inhibitor: a review. F1000Research 11:1115

doi: 10.12688/f1000research.125645.3

[14]

Ellsworth M, Ostrosky-Zeichner L. 2020. Isavuconazole: mechanism of action, clinical efficacy, and resistance. Journal of Fungi 6(4):324

doi: 10.3390/jof6040324

[15]

Handelman M, Osherov N. 2022. Experimental and in-host evolution of triazole resistance in human pathogenic fungi. Frontiers in Fungal Biology 3:957577

doi: 10.3389/ffunb.2022.957577

[16]

Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, et al. 2008. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. Clinical Infectious Diseases 46(3):327−360

doi: 10.1086/525258

[17]

Jenks JD, Hoenigl M. 2018. Treatment of aspergillosis. Journal of Fungi 4(3):98

doi: 10.3390/jof4030098

[18]

Zhou D, Korfanty GA, Mo M, Wang R, Li X, et al. 2021. Extensive genetic diversity and widespread azole resistance in greenhouse populations of Aspergillus fumigatus in Yunnan, China. mSphere 6(1):e00066-21

doi: 10.1128/msphere.00066-21

[19]

Sen P, Vijay M, Singh S, Hameed S, Vijayaraghvan P. 2022. Understanding the environmental drivers of clinical azole resistance in Aspergillus species. Drug Target Insights 16:25−35

doi: 10.33393/dti.2022.2476

[20]

Williams SL, Toda M, Chiller T, Brunkard JM, Litvintseva AP. 2024. Effects of climate change on fungal infections. PLoS Pathogens 20(5):e1012219

doi: 10.1371/journal.ppat.1012219

[21]

Rybak JM, Fortwendel JR, Rogers PD. 2019. Emerging threat of triazole-resistant Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy 74(4):835−842

doi: 10.1093/jac/dky517

[22]

Lockhart SR, Frade JP, Etienne KA, Pfaller MA, Diekema DJ, et al. 2011. Azole Resistance in Aspergillus fumigatus isolates from the ARTEMIS global surveillance study is primarily due to the TR/L98H mutation in the cyp51A gene. Antimicrobial Agents and Chemotherapy 55(9):4465−4468

doi: 10.1128/AAC.00185-11

[23]

Song Y, Buil JB, Rhodes J, Zoll J, Tehupeiory-Kooreman M, et al. 2025. Triazole-resistant Aspergillus fumigatus in the Netherlands between 1994 and 2022: a genomic and phenotypic study. The Lancet Microbe 6(8):101114

doi: 10.1016/j.lanmic.2025.101114

[24]

Chowdhary A, Kathuria S, Xu J, Meis JF. 2013. Emergence of azole-resistant Aspergillus fumigatus strains due to agricultural azole use creates an increasing threat to human health. PLoS Pathogens 9(10):e1003633

doi: 10.1371/journal.ppat.1003633

[25]

Cuypers L, Aerts R, Van de gaer O, Vinken L, Merckx R, et al. 2025. Doubling of triazole resistance rates in invasive aspergillosis over a 10-year period, Belgium, 1 April 2022 to 31 March 2023. Eurosurveillance 30(18):2400559

doi: 10.2807/1560-7917.es.2025.30.18.2400559

[26]

McCormick TS, Ghannoum M. 2024. Time to think antifungal resistance increased antifungal resistance exacerbates the burden of fungal infections including resistant dermatomycoses. Pathogens and Immunity 8(2):158−176

doi: 10.20411/pai.v8i2.656

[27]

Gerstein AC, Sethi P. 2022. Experimental evolution of drug resistance in human fungal pathogens. Current Opinion in Genetics & Development 76:101965

doi: 10.1016/j.gde.2022.101965

[28]

Zhang J, van den Heuvel J, Debets AJM, Verweij PE, Melchers WJG, et al. 2017. Evolution of cross-resistance to medical triazoles in Aspergillus fumigatus through selection pressure of environmental fungicides. Proceedings of the Royal Society B: Biological Sciences 284(1863):20170635

doi: 10.1098/rspb.2017.0635

[29]

Jacobs S, Boccarella G, van den Berg P, Van Dijck P, Carolus H. 2024. Unlocking the potential of experimental evolution to study drug resistance in pathogenic fungi. npj Antimicrobials and Resistance 2(1):48

doi: 10.1038/s44259-024-00064-1

[30]

Barber AE, Sae-Ong T, Kang K, Seelbinder B, Li J, et al. 2021. Aspergillus fumigatus pan-genome analysis identifies genetic variants associated with human infection. Nature Microbiology 6(12):1526−1536

doi: 10.1038/s41564-021-00993-x

[31]

Rhodes J, Abdolrasouli A, Dunne K, Sewell TR, Zhang Y, et al. 2022. Population genomics confirms acquisition of drug-resistant Aspergillus fumigatus infection by humans from the environment. Nature Microbiology 7(5):663−674

doi: 10.1038/s41564-022-01091-2

[32]

Wang F, Yao S, Cao D, Ju C, Yu S, et al. 2020. Increased triazole-resistance and cyp51A mutations in Aspergillus fumigatus after selection with a combination of the triazole fungicides difenoconazole and propiconazole. Journal of Hazardous Materials 400:123200

doi: 10.1016/j.jhazmat.2020.123200

[33]

Garcia-Rubio R, Gonzalez-Jimenez I, Lucio J, Mellado E. 2021. Aspergillus fumigatus cross-resistance between clinical and demethylase inhibitor azole drugs. Applied and Environmental Microbiology 87(5):e02539-20

doi: 10.1128/aem.02539-20

[34]

Wu G, Yang Q, Long M, Guo L, Li B, et al. 2015. Evaluation of agar dilution and broth microdilution methods to determine the disinfectant susceptibility. The Journal of Antibiotics 68(11):661−665

doi: 10.1038/ja.2015.51

[35]

Barrick JE, Lenski RE. 2013. Genome dynamics during experimental evolution. Nature Reviews Genetics 14(12):827−839

doi: 10.1038/nrg3564

[36]

Wagner MR, Kleiner M. 2025. How thoughtful experimental design can empower biologists in the omics era. Nature Communications 16:7263

doi: 10.1038/s41467-025-62616-x

[37]

Zhang J, Debets AJM, Verweij PE, Melchers WJG, Zwaan BJ, et al. 2015. Asexual sporulation facilitates adaptation: the emergence of azole resistance in Aspergillus fumigatus. Evolution 69(10):2573−2586

doi: 10.1111/evo.12763

[38]

Shoemaker WR, Lennon JT. 2022. Predicting parallelism and quantifying divergence in microbial evolution experiments. mSphere 7(1):e00672-21

doi: 10.1128/msphere.00672-21

[39]

Vogwill T, Kojadinovic M, Furió V, MacLean RC. 2014. Testing the role of genetic background in parallel evolution using the comparative experimental evolution of antibiotic resistance. Molecular Biology and Evolution 31(12):3314−3323

doi: 10.1093/molbev/msu262

[40]

Handelman M, Sarkar A, Varshavsky A, Shadkchan Y, Chen X, et al. 2026. Directed evolution of the pathogenic mold Aspergillus fumigatus reveals novel genes contributing to triazole resistance. Antimicrobial Agents and Chemotherapy 70(4):e01635-25

doi: 10.1128/aac.01635-25

[41]

Handelman M, Meir Z, Shadkchan Y, Abo Kandil A, Amano O, et al. 2024. Evolution of the pathogenic mold Aspergillus fumigatus on high copper levels identifies novel resistance genes. mSphere 9(6):e00253-24

doi: 10.1128/msphere.00253-24

[42]

Szendro IG, Franke J, de Visser JAGM, Krug J. 2013. Predictability of evolution depends nonmonotonically on population size. Proceedings of the National Academy of Sciences of the United States of America 110(2):571−576

doi: 10.1073/pnas.1213613110

[43]

Beredaki MI, Georgiou PC, Siopi M, Kanioura L, Andes D, et al. 2020. Toward harmonization of voriconazole CLSI and EUCAST breakpoints for Candida albicans using a validated in vitro pharmacokinetic/pharmacodynamic model. Antimicrobial Agents and Chemotherapy 64(6):e00170-20

doi: 10.1128/aac.00170-20

[44]

Wiederhold NP. 2021. Antifungal susceptibility testing: a primer for clinicians. Open Forum Infectious Diseases 8(11):ofab444

doi: 10.1093/ofid/ofab444

[45]

Salsé M, Gangneux JP, Cassaing S, Delhaes L, Fekkar A, et al. 2019. Multicentre study to determine the Etest epidemiological cut-off values of antifungal drugs in Candida spp. and Aspergillus fumigatus species complex. Clinical Microbiology and Infection 25(12):1546−1552

doi: 10.1016/j.cmi.2019.04.027

[46]

Carolus H, Sofras D, Boccarella G, Jacobs S, Biriukov V, et al. 2024. Collateral sensitivity counteracts the evolution of antifungal drug resistance in Candida auris. Nature Microbiology 9(11):2954−2969

doi: 10.1038/s41564-024-01811-w

[47]

Lestrade PPA, Meis JF, Melchers WJG, Verweij PE. 2019. Triazole resistance in Aspergillus fumigatus: recent insights and challenges for patient management. Clinical Microbiology and Infection 25(7):799−806

doi: 10.1016/j.cmi.2018.11.027

[48]

Segéňová I, Víglaš J, Pagáč T, Olejníková P. 2025. Adaptation under pressure: resistance and stress response interplay in clinical Aspergillus fumigatus isolates. Journal of Fungi 11(6):428

doi: 10.3390/jof11060428

[49]

Chen S, Zhu G, Lin H, Guo J, Deng S, et al. 2024. Variability in competitive fitness among environmental and clinical azole-resistant Aspergillus fumigatus isolates. mBio 15(4):e00263-24

doi: 10.1128/mbio.00263-24

[50]

Zeng M, Zhou X, Yang C, Liu Y, Zhang J, et al. 2023. Comparative analysis of the biological characteristics and mechanisms of azole resistance of clinical Aspergillus fumigatus strains. Frontiers in Microbiology 14:1253197

doi: 10.3389/fmicb.2023.1253197

[51]

Bing J, Hu T, Zheng Q, Muñoz JF, Cuomo CA, et al. 2020. Experimental evolution identifies adaptive aneuploidy as a mechanism of fluconazole resistance in Candida auris. Antimicrobial Agents and Chemotherapy 65(1):e01466-20

doi: 10.1128/aac.01466-20

[52]

Sandberg TE, Salazar MJ, Weng LL, Palsson BO, Feist AM. 2019. The emergence of adaptive laboratory evolution as an efficient tool for biological discovery and industrial biotechnology. Metabolic Engineering 56:1−16

doi: 10.1016/j.ymben.2019.08.004

[53]

Lofgren LA, Ross BS, Cramer RA, Stajich JE. 2022. The pan-genome of Aspergillus fumigatus provides a high-resolution view of its population structure revealing high levels of lineage-specific diversity driven by recombination. PLoS Biology 20(11):e3001890

doi: 10.1371/journal.pbio.3001890

[54]

Gerstein AC, Berman J. 2020. Candida albicans genetic background influences mean and heterogeneity of drug responses and genome stability during evolution in fluconazole. mSphere 5(3):e00480-20

doi: 10.1128/mSphere.00480-20

[55]

Kanellopoulos SG, Snelders E. 2025. Moving beyond multi-triazole to multi-fungicide resistance: broader selection of drug resistance in the human fungal pathogen Aspergillus fumigatus. PLoS Pathogens 21(2):e1012851

doi: 10.1371/journal.ppat.1012851

[56]

Lucas JA, Hawkins NJ, Fraaije BA. 2015. The evolution of fungicide resistance. In Advances in Applied Microbiology, Vol. 90. USA: Academic Press. pp. 29–92 doi: 10.1016/bs.aambs.2014.09.001

[57]

Stevenson EM, Gaze WH, Gow NAR, Hart A, Schmidt W, et al. 2022. Antifungal exposure and resistance development: defining minimal selective antifungal concentrations and testing methodologies. Frontiers in Fungal Biology 3:918717

doi: 10.3389/ffunb.2022.918717

[58]

Kowalski CH, Beattie SR, Fuller KK, McGurk EA, Tang YW, et al. 2016. Heterogeneity among isolates reveals that fitness in low oxygen correlates with Aspergillus fumigatus virulence. mBio 7(5):e01515-16

doi: 10.1128/mbio.01515-16

[59]

Paul S, Verweij PE, Melchers WJG, Moye-Rowley WS. 2022. Differential functions of individual transcription factor binding sites in the tandem repeats found in clinically relevant cyp51a promoters in Aspergillus fumigatus. mBio 13(3):e00702-22

doi: 10.1128/mbio.00702-22

[60]

Berger S, El Chazli Y, Babu AF, Coste AT. 2017. Azole resistance in Aspergillus fumigatus: a consequence of antifungal use in agriculture? Frontiers in Microbiology 8:1024

doi: 10.3389/fmicb.2017.01024

[61]

Verhasselt HL, Thissen L, Scharmann U, Dittmer S, Rath PM, et al. 2025. Trends of azole-resistant Aspergillus fumigatus susceptibility over 12 years from a German ECMM excellence center. Mycopathologia 190(2):34

doi: 10.1007/s11046-025-00941-x

[62]

Paul RA, Sadhasivam S, Frey T, Miller SA, Paul PA, et al. 2026. Azole resistance in Aspergillus fumigatus from diverse environments in Ohio, United States, is primarily driven by TR34/L98H and TR46/Y121F/T289A environmental signatures. Open Forum Infectious Diseases 13(4):ofag150

doi: 10.1093/ofid/ofag150

[63]

Snelders E, Celia-Sanchez BN, Nederlof YC, Zhang J, Kortenbosch HH, et al. 2025. Widely dispersed clonal expansion of multi-fungicide-resistant Aspergillus fumigatus limits genomic epidemiology prospects. mBio 16(6):e03652-24

doi: 10.1128/mbio.03652-24

[64]

Souza ACO, Ge W, Wiederhold NP, Rybak JM, Fortwendel JR, et al. 2023. hapE and hmg1 mutations are drivers of cyp51A-independent pan-triazole resistance in an Aspergillus fumigatus clinical isolate. Microbiology Spectrum 11(3):e05188-22

doi: 10.1128/spectrum.05188-22

[65]

Huber EM, Hortschansky P, Scheven MT, Misslinger M, Haas H, et al. 2022. Structural insights into cooperative DNA recognition by the CCAAT-binding complex and its bZIP transcription factor HapX. Structure 30(7):934−946.e4

doi: 10.1016/j.str.2022.04.001

[66]

Rybak JM, Xie J, Martin-Vicente A, Guruceaga X, Thorn HI, et al. 2024. A secondary mechanism of action for triazole antifungals in Aspergillus fumigatus mediated by hmg1. Nature Communications 15:3642

doi: 10.1038/s41467-024-48029-2

[67]

Berman J, Krysan DJ. 2020. Drug resistance and tolerance in fungi. Nature Reviews Microbiology 18(6):319−331

doi: 10.1038/s41579-019-0322-2

[68]

Cowen LE, Sanglard D, Howard SJ, Rogers PD, Perlin DS. 2015. Mechanisms of antifungal drug resistance. Cold Spring Harbor Perspectives in Medicine 5(7):a019752

doi: 10.17918/00008478

[69]

Starr TN, Flynn JM, Mishra P, Bolon DNA, Thornton JW. 2018. Pervasive contingency and entrenchment in a billion years of Hsp90 evolution. Proceedings of the National Academy of Sciences of the United States of America 115(17):4453−4458

doi: 10.1101/189803

[70]

Yazgan Z, Çalışkan R, Aygün G. 2025. Azole resistance in Aspergillus species isolated from clinical samples: a nine-year single-center study in Turkey (2015–2023). Journal of Fungi 11(9):659

doi: 10.3390/jof11090659

[71]

Chang Z, Yadav V, Lee SC, Heitman J. 2019. Epigenetic mechanisms of drug resistance in fungi. Fungal Genetics and Biology 132:103253

doi: 10.1016/j.fgb.2019.103253

[72]

Lee Y, Robbins N, Cowen LE. 2023. Molecular mechanisms governing antifungal drug resistance. npj Antimicrobials and Resistance 1:5

doi: 10.1038/s44259-023-00007-2

[73]

Ghosh D, Veeraraghavan B, Elangovan R, Vivekanandan P. 2020. Antibiotic resistance and epigenetics: more to it than meets the eye. Antimicrobial Agents and Chemotherapy 64(2):e02225-19

doi: 10.1128/aac.02225-19

[74]

Zhang Y, Zeng L, Huang X, Wang Y, Chen G, et al. 2025. Targeting epigenetic regulators to overcome drug resistance in the emerging human fungal pathogen Candida auris. Nature Communications 16(1):4668

doi: 10.1038/s41467-025-59898-6

[75]

Poudyal NR, Mehlem RT, Doneparthi P, Cady TL, Kaufman G, et al. 2026. A long noncoding RNA regulates in vitro and in vivo triazole antifungal susceptibility in Aspergillus fumigatus. Genetics 2026:iyag152

doi: 10.1093/genetics/iyag152

[76]

Valsecchi I, Mellado E, Beau R, Raj S, Latgé JP. 2015. Fitness studies of azole-resistant strains of Aspergillus fumigatus. Antimicrobial Agents and Chemotherapy 59(12):7866−7869

doi: 10.1128/AAC.01594-15

[77]

Zhang J, Debets AJM, Verweij PE, Snelders E. 2021. Azole-resistance development; how the Aspergillus fumigatus lifecycle defines the potential for adaptation. Journal of Fungi 7(8):599

doi: 10.3390/jof7080599

[78]

Keizer EM, Valdes ID, Forn-Cuni G, Klijn E, Meijer AH, et al. 2021. Variation of virulence of five Aspergillus fumigatus isolates in four different infection models. PLoS One 16(7):e0252948

doi: 10.1371/journal.pone.0252948

[79]

Burke MK. 2023. Embracing complexity: yeast evolution experiments featuring standing genetic variation. Journal of Molecular Evolution 91(3):281−292

doi: 10.1007/s00239-023-10094-4

[80]

Pérez-Torrado R, Querol A. 2016. Opportunistic strains of Saccharomyces cerevisiae: a potential risk sold in food products. Frontiers in Microbiology 6:1522

doi: 10.3389/fmicb.2015.01522

[81]

Bohner F, Papp C, Gácser A. 2022. The effect of antifungal resistance development on the virulence of Candida species. FEMS Yeast Research 22(1):foac019

doi: 10.1093/femsyr/foac019

[82]

Bermas A, Shapiro RS, Geddes-McAlister J. 2020. Experimental evolution of antifungal resistance in Cryptococcus neoformans. Current Protocols in Microbiology 59(1):e116

doi: 10.1002/cpmc.116

[83]

Cowen LE, Sanglard D, Calabrese D, Sirjusingh C, Anderson JB, et al. 2000. Evolution of drug resistance in experimental populations of Candida albicans. Journal of Bacteriology 182(6):1515−1522

doi: 10.1128/JB.182.6.1515-1522.2000

[84]

Carolus H, Pierson S, Muñoz JF, Subotić A, Cruz RB, et al. 2021. Genome-wide analysis of experimentally evolved Candida auris reveals multiple novel mechanisms of multidrug resistance. mBio 12(2):e03333-20

doi: 10.1128/mbio.03333-20

[85]

Todd RT, Forche A, Selmecki A. 2017. Ploidy variation in fungi: polyploidy, aneuploidy, and genome evolution. Microbiology Spectrum 5(4):funk-0051-2016

doi: 10.1128/microbiolspec.funk-0051-2016

[86]

Jay A, Jordan DF, Gerstein A, Landry CR. 2025. The role of gene copy number variation in antimicrobial resistance in human fungal pathogens. npj Antimicrobials and Resistance 3(1):1

doi: 10.1038/s44259-024-00072-1

[87]

Fan S, Li C, Bing J, Huang G, Du H. 2020. Discovery of the diploid form of the emerging fungal pathogen Candida auris. ACS Infectious Diseases 6(10):2641−2646

doi: 10.1021/acsinfecdis.0c00282

[88]

Todd RT, Soisangwan N, Peters S, Kemp B, Crooks T, et al. 2023. Antifungal drug concentration impacts the spectrum of adaptive mutations in Candida albicans. Molecular Biology and Evolution 40(1):msad009

doi: 10.1093/molbev/msad009

[89]

Bennett RJ, Forche A, Berman J. 2014. Rapid mechanisms for generating genome diversity: whole ploidy shifts, aneuploidy, and loss of heterozygosity. Cold Spring Harbor Perspectives in Medicine 4(10):a019604

doi: 10.1101/cshperspect.a019604

[90]

Morelli KA, Kerkaert JD, Cramer RA. 2021. Aspergillus fumigatus biofilms: toward understanding how growth as a multicellular network increases antifungal resistance and disease progression. PLoS Pathogens 17(8):e1009794

doi: 10.1371/journal.ppat.1009794

[91]

Daskalov A, Heller J, Herzog S, Fleißner A, Glass NL. 2017. Molecular mechanisms regulating cell fusion and heterokaryon formation in filamentous fungi. Microbiology Spectrum 5(2):funk-0015–2016

doi: 10.1128/microbiolspec.funk-0015-2016

[92]

Talapko J, Juzbašić M, Matijević T, Pustijanac E, Bekić S, et al. 2021. Candida albicans − the virulence factors and clinical manifestations of infection. Journal of Fungi 7(2):79

doi: 10.3390/jof7020079

[93]

Jenks JD, Tobin EH, Zahra F. 2026. Candida auris. StatPearls [Internet]. Treasure Island (FL), USA: StatPearls Publishing. www.ncbi.nlm.nih.gov/books/NBK563297/

[94]

Bottery MJ, van Rhijn N, Chown H, Rhodes JL, Celia-Sanchez BN, et al. 2024. Elevated mutation rates in multi-azole resistant Aspergillus fumigatus drive rapid evolution of antifungal resistance. Nature Communications 15(1):10654

doi: 10.1038/s41467-024-54568-5

[95]

Melo AM, Poester VR, Trápaga MR, Faria FA, Aquino V, et al. 2024. Aspergillus fumigatus sensu stricto genetic diversity from cystic fibrosis patients. International Journal of Medical Microbiology 317:151639

doi: 10.1016/j.ijmm.2024.151639

[96]

Zhou D, Liu Y, Zhang Q, Zhang Y, Xu J. 2026. Novel genetic diversity and geographic structures of Aspergillus fumigatus (Order Eurotiales, Family Aspergillaceae) in the karst regions of Guizhou, China. Microorganisms 14(1):237

doi: 10.3390/microorganisms14010237

[97]

Boyer J, Feys S, Zsifkovits I, Hoenigl M, Egger M. 2023. Treatment of invasive aspergillosis: how it's going, where it's heading. Mycopathologia 188(5):667−681

doi: 10.1007/s11046-023-00727-z

[98]

Marr KA, Schlamm HT, Herbrecht R, Rottinghaus ST, Bow EJ, et al. 2015. Combination antifungal therapy for invasive aspergillosis: a randomized trial. Annals of Internal Medicine 162(2):81−89

doi: 10.7326/M13-2508

[99]

Patterson TF, Thompson GR III, Denning DW, Fishman JA, Hadley S, et al. 2016. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clinical Infectious Diseases 63(4):e1−e60

doi: 10.1093/cid/ciw326

[100]

Lewis R, Niazi-Ali S, McIvor A, Kanj SS, Maertens J, et al. 2024. Triazole antifungal drug interactions − practical considerations for excellent prescribing. Journal of Antimicrobial Chemotherapy 79(6):1203−1217

doi: 10.1093/jac/dkae103

[101]

Colley T, Sehra G, Daly L, Kimura G, Nakaoki T, et al. 2019. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Scientific Reports 9(1):9482

doi: 10.1038/s41598-019-45890-w

[102]

Michel JB, Yeh PJ, Chait R, Moellering RC Jr, Kishony R. 2008. Drug interactions modulate the potential for evolution of resistance. Proceedings of the National Academy of Sciences of the United States of America 105(39):14918−14923

doi: 10.1073/pnas.0800944105

[103]

Mousavi B, Hedayati MT, Hedayati N, Ilkit M, Syedmousavi S. 2016. Aspergillus species in indoor environments and their possible occupational and public health hazards. Current Medical Mycology 2(1):36−42

doi: 10.18869/acadpub.cmm.2.1.36

[104]

Lightfoot JD, Adams EM, Kamath MM, Wells BL, Fuller KK. 2024. Aspergillus fumigatus hypoxia adaptation is critical for the establishment of fungal keratitis. Investigative Ophthalmology & Visual Science 65(4):31

doi: 10.1167/iovs.65.4.31

[105]

Emri T, Antal K, Varga K, Gila BC, Pócsi I. 2024. The oxidative stress response highly depends on glucose and iron availability in Aspergillus fumigatus. Journal of Fungi 10(3):221

doi: 10.3390/jof10030221

[106]

Luo Y, Liu F, Deng L, Xu J, Kong Q, et al. 2022. Innate and adaptive immune responses induced by Aspergillus fumigatus conidia and hyphae. Current Microbiology 80(1):28

doi: 10.1007/s00284-022-03102-1

[107]

Morton CO, Bouzani M, Loeffler J, Rogers TR. 2012. Direct interaction studies between Aspergillus fumigatus and human immune cells; what have we learned about pathogenicity and host immunity? Frontiers in Microbiology 3:413

doi: 10.3389/fmicb.2012.00413

[108]

Sun Y, Cui X, Zhang Y. 2026. The innate immune response to A. fumigatus in alveolar macrophages: Roles of LC3-associated phagocytosis, apoptosis and inflammation. Journal of Medical Mycology 36(1):101598

doi: 10.1016/j.mycmed.2025.101598

[109]

Furnica DT, Falkenstein J, Dittmer S, Steinmann J, Rath PM, et al. 2025. Human-like biofilm models to study the activity of antifungals against Aspergillus fumigatus. Microorganisms 13(9):2040

doi: 10.3390/microorganisms13092040

[110]

Fengler A, Bader O, Cornely O, Kurzai O, Meis JF, et al. 2026. Global epidemiology of azole resistance in Aspergillus fumigatus. JAC-Antimicrobial Resistance 8(1):dlaf219

doi: 10.1093/jacamr/dlaf219

[111]

Czuppon P, Day T, Débarre F, Blanquart F. 2023. A stochastic analysis of the interplay between antibiotic dose, mode of action, and bacterial competition in the evolution of antibiotic resistance. PLoS Computational Biology 19(8):e1011364

doi: 10.1371/journal.pcbi.1011364

[112]

Crocker J, Payne JL, Walczak AM, Wittkopp PJ. 2023. Interdisciplinary approaches to predicting evolutionary biology. Philosophical Transactions of the Royal Society B 378(1877):20220042

doi: 10.1098/rstb.2022.0042

[113]

Diaz-Colunga J, Skwara A, Gowda K, Diaz-Uriarte R, Tikhonov M, et al. 2023. Global epistasis on fitness landscapes. Philosophical Transactions of the Royal Society B 378(1877):20220053

doi: 10.1098/rstb.2022.0053

[114]

Daalman WKG, Sweep E, Laan L. 2023. A tractable physical model for the yeast polarity predicts epistasis and fitness. Philosophical Transactions of the Royal Society B 378(1877):20220044

doi: 10.1098/rstb.2022.0044

[115]

Escribano P, Recio S, Peláez T, González-Rivera M, Bouza E, et al. 2012. In Vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. Antimicrobial Agents and Chemotherapy 56(1):174−178

doi: 10.1128/AAC.00301-11

[116]

Hagiwara D, Takahashi H, Watanabe A, Takahashi-Nakaguchi A, Kawamoto S, et al. 2014. Whole-genome comparison of Aspergillus fumigatus strains serially isolated from patients with aspergillosis. Journal of Clinical Microbiology 52(12):4202−4209

doi: 10.1128/JCM.01105-14

[117]

Alcazar-Fuoli L, Buitrago M, Gomez-Lopez A, Mellado E. 2015. An alternative host model of a mixed fungal infection by azole susceptible and resistant Aspergillus spp strains. Virulence 6(4):376−384

doi: 10.1080/21505594.2015.1025192

[118]

Diaz Caballero J, Wheatley RM, Kapel N, López-Causapé C, Van der Schalk T, et al. 2023. Mixed strain pathogen populations accelerate the evolution of antibiotic resistance in patients. Nature Communications 14(1):4083

doi: 10.1038/s41467-023-39416-2

[119]

Shibai A, Furusawa C. 2024. Development of specialized devices for microbial experimental evolution. Development, Growth & Differentiation 66(7):372−380

doi: 10.1111/dgd.12940

[120]

Jago MJ, Soley JK, Denisov S, Walsh CJ, Gifford DR, et al. 2025. High-throughput method characterizes hundreds of previously unknown antibiotic resistance mutations. Nature Communications 16(1):780

doi: 10.1038/s41467-025-56050-2

[121]

Salem-Bango Z, Price TK, Chan JL, Chandrasekaran S, Garner OB, et al. 2023. Fungal whole-genome sequencing for species identification: from test development to clinical utilization. Journal of Fungi 9(2):183

doi: 10.3390/jof9020183

[122]

Caldera JR, Dayo A, Wiederhold N, Yang S. 2025. Development and validation of next-generation sequencing-based clinical test for triazole resistance prediction in Aspergillus fumigatus. Journal of Clinical Microbiology 63(8):e00291-25

doi: 10.1128/jcm.00291-25

[123]

Schiffer AM, Rahman A, Sutton W, Putnam ML, Weisberg AJ. 2025. A comparison of short- and long-read whole-genome sequencing for microbial pathogen epidemiology. mSystems 10(12):e01426-25

doi: 10.1128/msystems.01426-25

[124]

Hoyer LL, Freeman BA, Hogan EK, Hernandez AG. 2024. Use of a Candida albicans SC5314 PacBio HiFi reads dataset to close gaps in the reference genome assembly, reveal a subtelomeric gene family, and produce accurate phased allelic sequences. Frontiers in Cellular and Infection Microbiology 14:1329438

doi: 10.3389/fcimb.2024.1329438